Does your compound taste good enough for the clinic?
July 24, 2025

At Pharmidex, we offer Brief Access Taste Aversion (BATA) testing, which is a behavioural assay that quantifies how test subjects respond to different compounds or formulations by measuring lick response and aversion. This helps identify:


✅ Bitter-tasting APIs

✅ Unpalatable excipients

✅ The success of taste-masking strategies

✅ Formulation-dependent compliance risks


Get in touch if you’re developing oral formulations, paediatric drugs, or repurposing bitter APIs, this could be the data your IND package needs.

BATA Taste Aversion
BATA Taste Aversion

#DrugMetabolismServices #DrugDevelopmentServices #FormulationDevelopment #DrugDelivery #BATA #TasteAversion #Palatability #BehaviouralPharmacology

Pharmidex Histology Services: Precision You Can Trust
September 8, 2025
At Pharmidex , we deliver comprehensive histology solutions designed to support preclinical and clinical research with accuracy and reliability. 🔬 From sample to slide, our services include: tissue processing, embedding, microtomy, routine and special staining, digital imaging and slide scanning all underpinned by rigorous quality control and expert scientific oversight. With specialist capabilities and high-throughput workflows, we help researchers generate high-quality, reproducible data across toxicology, oncology, CNS and beyond. 👉 Learn more: pharmidex.com/histology
? Expanding our integrated capabilities in autoimmune research
September 3, 2025
At Pharmidex , we are proud to offer a comprehensive preclinical platform for autoimmune disease research. Using in vivo EAE models, we combine: ✔️ Bioanalysis & biomarker profiling to quantify key cytokines and mediators of disease progression ✔️ Histological assessment, enabling detailed evaluation of inflammation, demyelination and tissue pathology across multiple organs ✔️ Pharmacological intervention studies, including established treatments such as Fingolimod for validation This integrated approach delivers a complete and translationally relevant dataset, supporting drug discovery and development programmes from mechanistic insight through to therapeutic evaluation. By combining in vivo efficacy, biomarker analysis and histology, our team provides partners with a more comprehensive understanding of disease mechanisms and treatment effects. 👉 Learn more about our services in Histology, Biomarker Analysis, and Autoimmune Disease Models.
Pharmidex attending DMDG 51st Open Meeting 2025.
September 1, 2025
We’re delighted to share that Martin Barrett , our Head of Business Development, and Rob Jenkins , our Bioanalytical Scientist, will be attending the 51st Open Meeting 2025. This event is a fantastic opportunity to connect with industry leaders, share insights and build new collaborations. Martin and Rob are looking forward to meeting fellow attendees, exchanging ideas and exploring ways to create impactful partnerships that advance drug discovery and development. 🤝 If you’re attending, don’t hesitate to reach out they’ll be happy to connect, discuss your projects, and explore potential synergies.
More Posts